ʻO kahi maʻi mellitus ka maʻi koʻikoʻi o nā kaʻina metabola i loko o ke kino o ke kanaka. Hiki mai nā hōʻeha ma muli o ka lawa ʻole o ka insulin (kahi hormone i hana ʻia e ka pancreas) a i ʻole hōʻino paha i kona hopena ma nā ʻāpana a me nā ʻāpana. Malia paha he hopena hui pū ʻana o nā mea ʻelua.
Ua hoʻokaʻawale ʻia ka maʻi diabetes mellitus i kekahi mau ʻano me ke ʻano hoʻomohala ʻē aʻe, akā ʻo ka like like me ka hyperglycemia (piʻi i nā nui o ke kō o ke koko). ʻO ke ʻano 2 o ka maʻi he ʻano kūʻokoʻa like ʻole i ka insulin, ʻo ia hoʻi, ʻo ka ʻohi like o ka insulin e hoʻoliʻoli nei i ka nui o ka nui o ka insulin, akā ua pau nā naʻau o ke kino i ka naʻau o ia mea, ʻaʻole pane wale i kona hopena.
No ka mālamaʻana i ka maʻi diabetes type 2, ʻōlelo ʻo nā kauka e hoʻoponopono hou i ka ʻai o ka mea maʻi, me ka hoʻohana ʻana i ka nui o nā lāʻau lapaʻau e hoʻohaʻahaʻa i ke kō, a ke alakaʻi nei i kahi ʻano hana e hōʻemi ai i ka paona (e hoʻonui kēia i ka pono o ka ʻoihana). ʻO ka papa inoa o nā papa papa no ke ʻano maʻi type 2, a me nā hiʻohiʻona o kā lākou kumu a me ka intake, i noʻonoʻo ʻia i ka ʻatikala.
Nā hiʻohiʻona o ka hoʻohana ʻana i nā lāʻau
Hoʻomaʻamaʻa ʻia ka hopena o ka hoʻohana ʻana i nā lāʻau lapaʻau ma o ka ʻoihana laboratine a me ka instrumental diagnostics o ke kūlana o ka mea maʻi. ʻO nā pahuhopu e hele ai i nā poʻe loea i:
- piʻi kiʻekiʻe i ka glycemia a hiki i ka 5.6 mmol / l;
- iʻoi aku ka wai ʻai kakahiaka ma mua o 5.5 mmol / l;
- mau helu o ka hemoglobin glycated a i ka 5.9%, ka maikaʻi loa o nā mea āpau - 5,5% (me kēia hōʻailona, ʻo ka loaʻa o ka hoʻomohala ʻana i ka hopena o ka maʻi diabetes) he ʻumi;
- nā helu maʻamau a me nā mea'ē aʻe e komo ai i ka lipid metabolism;
- ʻaʻole kiʻekiʻe ka piʻi o ke koko ma mua o 130/85 mm RT. Art., Nele i nā pōʻai hypertensive;
- ka hoʻōla maʻamau o vascular elasticity, ka nele o nā lesi atherosclerotic;
- nā hōʻailona kūpono loa o ke kōkiko koko;
- acuity ʻike maikaʻi, ka haʻalele o kona hoʻohaʻahaʻa;
- ka pae maʻamau o ka hana noʻonoʻo a me ka ʻike;
- ka hoʻihoʻi ʻana o ka naʻau o ka hopena o nā haʻahaʻa haʻahaʻa, ka hemahema o nā ulcerations trophic ma ka ʻili.
ʻO nā lāʻau lapaʻau nui i hoʻohana ʻia e mālama ai i nā patology
Aia kahi pūʻulu nui o nā lāʻau lapaʻau i hoʻokaʻawale ʻia i nā puʻupuʻu pūʻulu. Hoʻokomo ʻia nā lāʻau Hypoglycemic (hypoglycemic) e hoʻoulu i nā helu kiʻekiʻe o ka glucose i ke kahe koko. Lunamakaainana:
- lepo;
- ololilurea derivatives.
ʻO nā lāʻau lapaʻau o kēia hui kahi mea e hoʻoikaika ai i ka synthesis o ka insulin hormone e ka pancreas. Ua hoʻonohonoho ʻia lākou i waiho wale ʻia ma ke ʻano o nā hana hana o ka apu apana insular. ʻO kā lākou hopena maikaʻi loa ma ke kino o ka mea maʻi e hiki i ka mea maʻi ke loaʻa ka momona ma muli o ka wai a me ka paʻakai paʻakai, a hiki i nā lāʻau lapaʻau ke hōʻeha i ka hoʻoliʻiliʻi o ke kō.
ʻO ka hui ʻelua o nā lāʻau lapaʻau nā mea antihyperglycemic agent. ʻAʻole pili ka poʻe ʻelemaka o kēia mau papa lāʻau i ka hana o ka ʻenehana insular, akā pale lākou i ka hoʻonui ʻana i nā helu glucose ma o ka hoʻonui ʻana i kona ʻai e nā cell peripheral a me nā kiko. Nā ʻelele o ka hui:
- thiazolidinediones;
- biguanides;
- ʻO nā inhibitor α-glucosidase.
ʻO ka endocrinologist mākaukau nāna i aʻo i nā ikela olakino a me noiʻi e pili ana i ka mea maʻi e koho i kahi hoʻoponopono lāʻau
ʻO nā ʻokoʻa nui ma waena o nā lāʻau
Ke koho ʻana i nā papa maikaʻi loa no ka diabetes mellitus type 2, ke loiloi nei ke kauka i ko lākou hiki ke hoʻomohala i ka pae o ka hemoglobin glycosylated. ʻO nā helu liʻiliʻi he mau hiʻohiʻona o ka inhibitors o α-glucosidase a me nā glinid inhibitors. ʻO nā kumu HbA1C i ka wā mālama e hōʻemi ʻia e 0.6-0.7%. Noho ka Thiazolidinediones i ka lua o ka hana. Kūʻē ka HbA1C i ka hope o kā lākou intake i hōʻemi ʻia e 0.5-1.3%.
I ka wahi mua, nā derivatives o nā sulfonylureas a me nā biguanides. Ke hana nei i ka mālamaʻana me kēia mau lāʻau e hiki ke hōʻemi i ka hōʻemi o ka pae o ka hemoglobin glycosylated e 1.4-1.5%.
Hōʻike pinepine ʻia ʻo Glycated (glycosylated) hemoglobin maʻamau i nā glycemia maʻamau i nā lā 90 i hala iho nei.
He mea nui e noʻonoʻo i ka hana o ka hana a nā lāʻau lapaʻau i kā lākou papa lāʻau. Hoʻohana ʻia nā inhibitor Α-glucosidase inā he mea maʻamau ka maʻi o ka mea maʻi ma mua o nā huahana i ke kino, akā hyperglycemia hoʻokahi hola ma hope o kēia kaʻina hana. ʻO ke ʻano kūlike ka maʻamau no ka hoʻohana ʻana iā biguanides: kiʻekiʻe glucose ma mua o ka meaʻai i hui pū ʻia me nā helu maʻamau ma hope o ka ʻaina.
Hāpai nā Endocrinologists i ke kaumaha o ke kanaka maʻi. No ka laʻana, ʻaʻole i ʻōlelo ʻia ka derivatives o sulfonylurea no ka mālamaʻana i ka maʻi maʻi i ka maʻi hānai, ʻaʻole hiki ke ʻōlelo ʻia e pili ana i ka thiazolidinediones. Hoʻohana kūpono kēia mau kālā no ka paona kino o nā mea maʻi no ka mea maʻi. Hōʻike ka mea i lalo i nā hiʻohiʻona o kēlā me kēia hui o nā lāʻau lapaʻau no ka maʻi type 2.
Itors-glucosidase inhibitors
ʻO nā ʻelele o nā ʻaina antihyperglycemic e hana ana i ke kiʻekiʻe o ka gastrointestinal tract. Hiki i ka ʻenehana lawaiʻa Lūkini i hiki ke hāʻawi aku i hoʻokahi koho o ka inhibitors - ʻo ka lālani Glucobay (acarbose). ʻO ka mea ikaika, he ʻāpana o ka lāʻau lapaʻau, nakinaki i nā enzyme o ka pūpū liʻiliʻi, ke hoʻolohi nei i nā kaʻina hana o ka hoʻokaʻawale ʻana a me ka hoʻowalewale ʻana o nā hāmeʻakama maʻalahi.
Ua ʻike ʻia hiki i ka acarbose ke hōʻemi i ka hopena o ka hōʻino o ka puʻuwai a me nā moku koko. ʻAʻole i aʻo ʻia ka mīkini o kāna hana, eia nō naʻe ke hōʻike nei i ke ʻano o ka waiwai i ke kū ʻole ʻana i ka hana o ke kō e nā selu a me nā kaʻina hana hoʻohana glucose i ka periphery.
Hoʻohui pū ʻia ʻo Glucobai:
- me ka hopena o ka insulin;
- biguanides;
- ololilurea derivatives.
Inā lawe ka mea maʻi i ka ulana a me ka hoʻomākaukau hoʻomākaukau ʻana e pili ana i ka hoʻihoʻi ʻana o nā enzyme i ka manawa like me kēia pūʻulu o nā lāʻau lapaʻau, hoʻoneʻe ʻia ka hana o ka inhibitors. Pono e mālama i kēia ʻoiaʻiʻo i ka wā e kahakiʻi ai i kahi hoʻoponopono lapaʻau.
Ke kāpena-iho - ʻaʻole i ʻae ʻia, e nīnau aku i kekahi kauka ma mua o ka kūʻai ʻana i kahi lāʻau lapaʻau
ʻAʻole hiki ke hoʻohana ʻia ʻo Glucobai no ka maʻi type 2 no ka mea aia kahi ma lalo iho nei:
- nā maʻi ʻeha o kahi ʻano kūlohelohe;
- colitis ulcerative;
- pani ʻia i kahi ʻāpana o ka ʻāpana;
- ka maʻi kaumaha o ka ate.
Biguanides
I kēia manawa, ʻaʻohe hoʻohana nui o biguanides i loko o Lūkini e like me nā ʻāina ʻē. Ua pili kēia me ka nui o ka hopena o ka lactic acidosis ma ka hope o ka mālama. ʻO Metformin ka ipu maikaʻi loa a ʻoi loa ka palekana no ka maʻi maʻamau ʻo 2, ka manawa i hoʻohana pinepine ʻia i nā manawa āpau ma mua o nā mea āpau o ka pūʻulu.
Ke hoʻomau nei nā haʻawina hoʻokolohua i kahi noi ʻana hohonu o ka hana a nā mea ikaika e hana ai i nā biguanides. Ua ʻike ʻia ʻaʻole pili ka lāʻau lapaʻau i ka hana o nā mea hana insularus, akā i ka heleʻana o ka insulin hormone, hoʻonui lākou i ka hoʻowalewale o ka suka e nā ʻōpū a me nā momona momona. Hana ka Metformin i nā mea ʻokoʻa o nā selipila peripheral, e hoʻonui ana i kā lākou helu a hoʻonui i ka ʻike ʻana i ka hana o nā mea lāʻau hormone.
Hāʻawi ʻia kēia mau pilia maʻi maʻi 2 i kēia mau pilikia:
Papa inoa 2 lapaʻau lāʻau lapaʻau papa inoa- kaumaha kaumaha kiʻekiʻe;
- ka waha ʻole o ka mālama ʻana me nā hui ʻē aʻe o nā mea maʻi hypoglycemic;
- ka pono ke hoʻonui i ka hopena o nā lāʻau lapaʻau ke hoʻohui ʻana i kekahi mau lāʻau lapaʻau.
Hiki ke hoʻohana i ka metformin no ka monotherapy. Eia kekahi, hoʻonā ʻia ka lāʻau lapaʻau e pale i ka hoʻomohala ʻana o kahi "ʻaha ʻoluʻolu" i kahi o ke ahulau o ka hoʻomanawanui o ka hoʻonaninaniʻana i nā glucose, nā mea maʻi me nā maʻi a me nā mea maʻi me nā pathology mai ka lipid metabolism.
Hoʻokomo ʻia ka lāʻau lapaʻau me ka maʻi maʻi me ka biguanides i kēia mau kūlana:
- ʻO ka maʻi diabetes mellitus type 1 me ka makemake e hoʻomohala i kahi kāmele ketoacidotic;
- ka hoʻēmi ʻana o ka maʻi o ka maʻi;
- pathology mai ka pūpū a me ka hāmeʻe i hana;
- ka mālama ʻia ʻana o ka maʻi maʻi maʻi type 2 i nā mea maʻi maʻi;
- ka lawa ʻole o nā māmā a me ka puʻuwai naʻau;
- atherosclerotic vascular lesions;
- hypoxia o kekahi kumu;
- wā hāpai;
- ka pono no ka hāʻawi ʻana i ka maʻi hana;
- waiʻona.
ʻO ka hiʻohiʻona o nā kino ketone kekahi o nā contraindications i ka mālama ʻia me nā ʻaoʻao papa
Sulfonylureas
ʻO kēia mau lāʻau no ka mālamaʻana i nā maʻi diabetes type 2 i loaʻa ka hopena hypoglycemic hoʻolaha nui. Aia ma mua o 20 mau inoa o nā ʻelele o nā hui i ʻike ʻia, i hoʻokaʻawale ʻia i kekahi mau hanauna. ʻO ka hopena o nā sulfonylureas kahi hopena i loko o nā pūnao insular, ka mea e hoʻoulu ai i ka hoʻokuʻu ʻana o ka hormone a hoʻokuʻu i kona kahe koko.
Hiki i kekahi mau derivatives sulfonylurea ke hoʻonui i ka nui o nā mea i nānā i ka insulin i nā cell peripheral, e hōʻemi ana i ka pale ʻana o ka hopena i ka hormone. ʻO nā mea a nā hui i kau ʻia no ka maʻi type 2.
- He hanauna koʻu - Chlorpropamide, Tolbutamide;
- ʻElua hanauna - Glibenclamide, Glyclazide, Glimepiride.
Hiki ke hoʻohana ʻia nā derivatives o ka sulfonylureas ma ke ʻano o ka monotherapy a me ka hoʻohui pū me nā mea maʻi ʻē aʻe e hoʻemi ana i ke kō koko. ʻAʻole ʻae ʻia ka hoʻohana ʻana o ʻelua mau mea mai ke ʻano like o nā lāʻau lapaʻau.
Hoʻomaʻamaʻa maikaʻi ka Therapy e nā maʻi maʻi maʻi maʻi. I kekahi mau hihia, hiki i nā mea maʻi ke hoʻopiʻi aku i nā hōʻekepili o ka hōʻemi koʻikoʻi i ka glycemia. I nā poʻe kahiko, ke piʻi aʻe ka pilikia o ka hoʻouluʻana o ka hypoglycemia ma ka hapalua, i pili pū me ka loaʻa ʻana o nā maʻi paʻakikī o ka maʻi lalo, ka hoʻohana ʻana i nā lāʻau lapaʻau ʻē aʻe, a me ka hoʻohana ʻana o nā liʻiliʻi liʻiliʻi.
ʻO nā hopena ʻē aʻe i ka hopena o ka maʻi:
- nā pāpā o ka luaʻi;
- anorexia;
- ʻiliʻili ʻo ka ʻili a me ke sclera;
- nā ninia
- nā pulu ʻili;
- loli ma ka helu koko helu helu.
Ke lawe ʻia nei ka lāʻau lapaʻau ʻo nā maʻi diabetes type 2 o ka mellitus me ka derivatives o ka sulfonylurea i loko o ka manawa o ka gestation a me ka lactation, me ka pōʻino koʻikoʻi i ka ʻāpana renal, e kū'ē ana i kahi kūlana o kahi ʻano hana i paulinine ʻia o ka maʻi.
Nā Hoʻopiha
He mau keʻena ʻōlelo nonsulfonylurea lākou. Hōʻike ʻia ka pūʻulu e nā lāʻau lapaʻau Nateglinide a Repaglinide. Ke hoʻomake nei nā lāʻau lapaʻau i ke kōpaʻa koko ma hope o ka ʻai ʻana, ʻaʻole i hoʻonāukiuki i ka hoʻouka ʻana o ka hōʻemi nui o ka glucose. ʻO nā manawa maikaʻiʻole o ka mālamaʻana he hana hoʻohaʻahaʻa haʻahaʻa ka hoʻohālikelike, kahi e hoʻohālikelike ai me nā hana a α-glucosidase inhibitors, he koʻikoʻi nui e hoʻonui i ka paona o ka mea maʻi, a me kahi hōʻemi o ka hopena o ka hopena ma luna o kona lōʻihi.
Nā maʻi hoʻohālikelike i ke koho ʻana i nā lāʻau lapaʻau.
- ka heleʻana o kēlā hypersensitivity o nā mea ikaika;
- insulin-puka waha o ka maʻi;
- hapai a lactation;
- ʻO nā kūlana palena o nā patula a me nā ate;
- makahiki liʻiliʻi o ke kanaka maʻi;
- nā maʻi maʻi ʻelemakule (ma mua o 73-75 mau makahiki).
Nā hiʻohiʻona o ka hoʻohana ʻana i ka pālolo (hiki paha i ke kauka ke nānā aku i ka nui a me ka ʻole o ka hoʻokele)
Nui! I kekahi mau hihia, ulu paha nā maʻi maʻi. Ma ke ʻano he kānāwai, me ka hypersensitivity pilikino a i ʻole kūlike i ke ʻano o ka hui ʻana o ka pālolo me nā lāʻau lapaʻau ʻē aʻe.
Nā ʻōwili
Hōʻike ʻia nā Hormones i nā lāʻau ikaika-hāmeʻa o ka gastrointestinal tract, e hoʻoikaika ai i ka hana o ka insulin. ʻO kekahi o nā ʻelele o nā lāʻau lapaʻau hou ʻo Sitagliptin (Januvia). Hoʻolālā ʻia ʻo Sitagliptin no ka monotherapy a me ka hoʻohui hoʻohui ʻana i ka hui me ka sulfonylureas, biguanides.
ʻO ke kuhikuhi ʻana i ka lāʻau lapaʻau i ka poʻe ʻelemakule, ʻaʻohe pono ka hoʻoponopono ʻia ʻana: no nā keiki a me nā wā ʻōpio, ʻaʻole i hoʻohana ʻia ʻo Sitagliptin i ka mālama ʻana. Ua hōʻike ʻia nā haʻawina haukapila e hiki i nā mea huaʻai ke hōʻemi i ka hemoglobin glycosylated ma luna o 90 mau lā e 0.7-0.8%, ke hoʻohana nei ʻo Metformin - ma ka 0.67-0.75%.
Hoʻopiha nā pahuhopu i nā hopena lōʻihi:
- nā hana ʻeha o ka papahele o ka ʻōpū;
- nā ninia
- cephalgia;
- kūlana maʻi hypoglycemic.
ʻO nā lāʻau lapaʻau ʻē aʻe i hoʻohana ʻia no ka maʻi diabetes type 2
Ma ka hoʻohālikelike ʻana i nā papaʻaila kōkuhi.
- nā lāʻau antihypertensive - nā lāʻau lapaʻau e hakakā i nā helu kiʻekiʻe o ke koko;
- vaso- a me ka cardiotonics - e kākoʻo i ka hana o ka puʻuwai a me nā kīʻaha koko;
- Nā lāʻau lapaʻau enzymatic, pre- a me probiotics - ʻo ia hoʻi e kākoʻo i ka hana ʻana o ke aʻalopala ʻōpala;
- anticonvulsants, anesthetics kūloko - hoʻohana ʻia e pale i nā hoʻopiʻi o ka maʻi mellitus (polyneuropathy);
- anticoagulants - pale i ka thrombosis;
- statins a fibrates - nā lāʻau lapaʻau e hoʻihoʻi i nā hana o nā hana momona, e hoʻoneʻe ana i ka kolamu nui mai ke kino.
I kahi helu nui o nā lāʻau lapaʻau, hiki i nā nephroprotectors a me nā mea i hoʻopili ʻia i nā meaʻai e hoʻohui ʻia, kahi e ʻae ʻia e hoʻohana ʻia, akā aia wale nō ma lalo o ka mālama ʻana o ka endocrinologist kūpono.
ʻO ka lāʻau antihypertensive
ʻO ke kahe koko kiʻekiʻe kekahi o nā maʻi maʻamau e kū mai ana i ke ʻano o kahi "maʻi aloha". Nā ʻōhumu o kēia ʻano e hiki aku ana ma mua o ke kiʻi o ke kikowaena o ka maʻi lalo.
Hoʻonui ka hypertension i ka pilikia o ka hoʻopiʻi ʻana mai ka naʻau, nā kīʻaha koko, a me nā pōpoki he mau manawa i mau manawa, no laila, pono ia i ka hoʻoponopono koke ʻana.
Ke pale aku i nā helu koko nui, ua kuhikuhi ʻia nā pūʻulu o nā lāʻau antihypertensive:
- ACE inhibitors (Creensril, Enalapril) - loaʻa i kahi hopena nephroprotective, e pale i ka naʻau a me nā kīʻaha koko, e hōʻemi i ka pale ʻana o nā umauma a me nā ʻoka i ka hormone o ka pancreas.
- Diuretics (thiazides a me diuretics loop) - nā lāʻau lapaʻau o kēia pūʻulu e hōʻemi i ka ikaika, akā ʻaʻole e kāpae i ka etiological factor iho, kahi i alakaʻi ai i kahi kūlana hypertensive.
- β-blockers (Nebilet, Carvedilol) - pākia i nā ʻona i loko o ka puʻuwai a me nā mea hoʻonaninani.
- Nā antagonis kaleta (Verapamil, Nifedipine) - nā lāʻau lapaʻau e hoʻonui i ka lumen vascular, ho'ēmi i nā hōʻike o albuminuria, proteinuria.
- ʻO nā Antagonist o RA-II (Mikardis, Losartan) - e pili ana i nā inhibitor ACE, ʻoi aku ka maikaʻi o nā mea maʻi.
ʻO statitis a me nā fibrates
Hoʻohana ʻia nā mākaukau a kēia mau hui e kaua i nā leʻe vart atherosclerotic. E hana ana nā statins i ke kaʻina o ka hoʻokumu ʻana i ka cholesterol ma ke kahua hepatic. Kuhi ʻia ka hana o nā lāʻau lapaʻau e hōʻemi i nā helu o ka triglycerides a me ka cholesterol, ka hoʻihoʻi ʻana o nā pōkole e kū ana ma ka ʻaoʻao o nā arteri a hoʻopili i ka venne lumen.
Nui! Hoʻopilikia ka lōʻihi lōʻihi i ka mālamaʻana i ka hōʻeha o ka naʻau a me ka make e ka hapakolu.
Hoʻomaʻamaʻa maikaʻi nā statins e nā maʻi. ʻAʻole ia i hōʻike ʻia no nā maʻi pepeha hōʻeha, i ka manawa o ka hānau ʻana i kahi keiki, me ka ʻokiʻoki.Pono mau ka Therapy i ka manawa mau loa, ʻo ka hōʻole ʻana i ka lāʻau lapaʻau no 30 mau lā a i ʻole e hoʻi i nā pae kolikoli i kā lākou helu helu mua ma mua.
Hoʻonui ka fibrates i ka hana o kahi mea pono enzymatic e hoʻopilikia i ka papa o nā hana lipid. E kū'ē i ke ʻano o ko lākou intake, ua hoʻemi ʻia nā helu cholesterol e kahi hapakolu, triglycerides - e 20%, i kekahi manawa ma ka hapalua hoʻi. Pono ka hoʻomaʻamaʻa ʻana o nā maʻi maʻi i ka hoʻoponopono ʻana i ka dosage.
Neuroprotectors
E kū'ē i ka kiʻi o kahi "maʻi aloha", hiki ke hōʻino ʻia i ka pūnao nā nūnē, e hōʻike ʻia ana e kēia mau ʻano:
- encephalopathy maʻi maʻi;
- neʻe weli;
- neuropathies maʻi maʻi maʻi;
- symmetric distal polyneuropathy;
- polyneuropathy ʻona;
- maʻiila maʻi diabetes;
- cranial neuropathy;
- o nā hoʻopiʻi neurological ʻē aʻe.
Ke hoʻopilikia nei ka peripheral NS, hoʻopiʻi nā poʻe maʻi i ka ʻeha o ka wāwae, goosebumps, a me ka nānā ʻana
ʻO kekahi o nā lāʻau hoʻohana maikaʻi loa e hoʻihoʻi i nā kaʻina metabolic ma kēia wahi ʻo Actovegin. Mālama i ka lāʻau lapaʻau i ke kahe o ke koko, hoʻopau i ka pololi o ka oxygen star of cells, e hoʻolako i ka lawe ʻana i nā glucose i nā wahi pōloli i ka nui o ka lolo.
ʻO ka lāʻau lapaʻau e hiki mai ana ma Instenon. ʻO kēia kahi nootropic me nā hopena vascular a me nā neurometabolic. Kākoʻo ka mea hana i ka hana o nā pūnao o nā nerve i nā kūlana o ka loaʻa o ke koko a me ka nele o ka oxygen.
Eia kekahi, hoʻohana ʻia nā lāʻau e pili ana i ka thioctic acid (Berlition, Espalipon). Hiki iā lākou ke nakinaki a wehe i nā radical free, hoʻoulu i ka hoʻihoʻi ʻana o ka sheelin sheathin, a hoʻohaʻahaʻa i ka pae o ka triglycerides a me ka kolamu i ke koko. Pono nā poʻe loea i ka vitamina B-series, nā lāʻau anticholinesterase i ka hoʻopili ʻana o ka hoʻomohala.
ʻO ka hoʻāʻo ʻana iho i kahi ʻano like ʻole o ka maʻi like ʻole o ka insulin, ʻoiai i ka ʻoluʻolu, ʻaʻole i ʻae ʻia, ʻoiai ua hiki i kēia ke ʻeha i ke ʻano o nā pathological. He mea nui ia e kākau ka endocrinologist i ka regimen lapaʻau ma hope o ka hoʻopaʻa ʻana o ka hoʻopaʻa ʻana o ka maʻi o ka mea maʻi.
